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1. Introduction 
The strength of the mechanisms involved in the control of health and lifespan determines 
the rate of aging in any organism. Aging is fueled by the accumulation of damage in a 
multitude of tissues, causing many age-related diseases including cardio-vascular diseases, 
neuro-degenerating diseases, metabolic syndrome and cancer[1]. We know that a healthy 
life-style, good habits, exercise and positive attitude are all factors that support a healthy, 
long life while the consumption of unhealthy, low nutritional and high caloric diet, bad 
ecology, bad habits and constitutive stress are known to shorten life and lead to the 
accumulation of a number of pathologies. However, exposure to low level stresses, for 
example induced by exercise, increases our resistance to detrimental stress insults, this 
process is referred to as hermesis[2]. With respect to what is beneficial and what is 
detrimental for health, we still do not fully understand the underlying processes that 
support our health and long life nor what allows us to become more resistant to a constantly 
changing, and sometimes unfriendly, environment. 
The causative link between aging and age-related diseases emphasizes how 
understanding the mechanisms that control aging could aid in the development of 
approaches for the prevention and treatment of many human diseases. The involvement 
of similar signaling pathways in the control of aging and defense against different 
diseases supports this concept. Two protein kinases, Target of Rapamycine (TOR) and 
AMP-activated protein kinase (AMPK), are central regulators of aging that are often 
found to be malfunctioned in many human diseases and, according to different animal 
models, play a role in cancer, diabetes, neurodegeneration and other syndromes[3, 4]. 
Strikingly, AMPK directly regulates the TOR activity, indicating that these proteins have 
overlapping functions and are involved in the same pathways[3]. The proteins involved in 
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the AMPK activation and the TOR suppression are potential regulators of longevity and 
aging. Among the modulators of AMPK and TOR, tumor suppressors p53 and members 
of the Forkhead Box O (FoxO) family play a central role in defense from stress, 
determination of lifespan and protection from age-related pathologies via activation of the 
stress-responsive Sestrin genes.  
2. The function of the AMPK –TOR pathway and its role in lifespan 
regulation  
2.1. TOR 
The kinase TOR was originally identified as protein that can be inhibited by rapamycin, a 
macrolid found in the soil of Easter island, named after local name for the island - Rapa 
Nui[5]. Rapamycin is produced by the bacteria Streptomyces hygroscopicus and acts as an 
antifungal metabolite. Mutagenesis analysis in Saccharomyces cerevisiae led to the isolation of 
strains resistant to rapamycin and the identification of the two genes TOR1 and TOR2 that 
are responsible for this effect[5]. TOR genes encode proteins belonging to 
phosphatidylinositol kinase-related kinase (PIKK) family of Ser/Thr protein kinases[5]. 
Protein products of TOR genes form two complexes called TOR complex-1 (TORC1) and 
TOR complex-2 (TORC2)[5]. Later TOR orthologs were identified in all studied eukaryotic 
organisms including mammals, although the mammalian genome contains only one 
functional TOR gene (mammalian TOR or mTOR)[5]. The mammalian TORC1 (mTORC1) 
and TORC2 (mTORC2) complexes share several subunits: mTOR itself, lethal with Sec13-
protein 8 (mLST8, also known as GL), DEP-domain containing mTOR-interacting protein 
(DEPTOR) and Tti1/Tel2[3]. TORC1 contains unique regulatory-associated protein of mTOR 
(raptor) and proline-rich Akt-substrate 40 kDa (PRAS40)[3]. TORC2 includes the rapamycin-
insensitive mTOR companion (rictor), mammalian stress-activated MAP kinase-interacting 
protein-1 (mSIN1) and protein observed with rictor-1 and -2 (protor1/2)[3, 6]. Raptor and 
Rictor determine the specificity of mTORC1 and mTORC2 toward their substrates that are 
responsible for mTOR-dependent processes[5, 6]. Among the two complexes, mTORC1 is 
sensitive to inhibition by rapamycin, although prolonged rapamycin treatment can also 
inhibit mTORC2[6]. Rapamycin inhibits mTORC1 via interaction with 12 kDa FK506-
binding protein (FKBP12), which in complex with rapamycin, binds and inhibits 
mTORC1[5] (Fig.1). 
mTORC1 and mTORC2 have different substrate specificity, dictated by different subunit 
composition. Two well-established substrates of mTORC1 are S6 kinase-1 (S6K1) and the 
eukaryotic translation initiation factor (eIF) 4E (eIF4E) binding protein-1 (4EBP1), 
involved in regulation of protein synthesis [3] (Fig.1). S6K was originally identified as a 
kinase phosphorylating ribosomal S6 protein although other substrates involved in the 
regulation of protein translation were discovered later. Among the targets of S6K1 that 
support translation initiation and elongation, are eukaryotic elongation factor 2 kinase, 
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(eEF2K), S6K Aly/REF-like target (SKAR), and 80 kDa nuclear cap-binding protein 
(NCBP1) and eIF4B. eIF4B, activated via S6K-dependent phosphorylation, stimulates the 
activation of eukaryotic translation initiation factor 4A (eIF4A), an RNA helicase that 
enhances translation, unwinding structured 5’-untranslated regions of many RNA[6]. 
4EBP1 is another regulator of translation which, in its hypo-phosphorylated form, 
inhibits initiation of cap-dependent translation via interaction with cap-binding protein 
eIF4E, a component of eIF4F translation initiation complex. When phosphorylated by 
mTORC1, 4EBP1 dissociates from eIF4E allowing recruitment of translation initiation 
factor eIF4G and the subsequent stimulation of protein synthesis[3]. mTORC1 also 
phosphorylates unc-51-like kinase-1 (ULK1/ATG1) and mammalian autophagy-related 
gene-13 (ATG13), the components of ULK1/ATG13/FLP200(focal adhesion kinase family-
interacting protein of 200 kDa) required for the activation of autophagic proteolysis 
(Fig.1). mTORC1 also regulates other proteins involved in autophagy such as suppressor 
of autophagy death-associated protein-1 (DAP1) and regulator of early autophagosome 
formation WIPI2, a mammalian ortholog of yeast Atg18. Additionally, mTORC1 is 
involved in lysosomal biogenesis through phosphorylation and inhibition of 
transcription factor EB (TFEB)[3].  
The mTORC2 substrates appear to be members of AGC kinase family which includes AKT, 
serum- and glucocorticoid-induced protein kinase-1 (SGK1), and protein kinase C- (PKC), 
involved in the regulation of metabolism and viability. AKT, phosphorylated by mTORC2 
in hydrophobic motif on Ser473, is an important regulator of metabolism and cell viability, 
while SGK1 controls growth and ion transport, and PKC is involved in actin cytoskeleton 
regulation via paxilin and Rho GTPases[3, 7].  
The mTOR-containing complexes have different, although in some aspects overlapping, 
functions[5, 6]. mTORC1 supports many anabolic processes in the cells such as protein and 
lipid biosynthesis, and ribosomal biogenesis[5]. mTORC1 also influences energy 
metabolism through the stimulation of mitochondrial respiration and glycolysis[8-
11](Fig.1). The importance of mTOR in mitochondrial function is supported at several 
levels of control including: (i) regulation of mitochondrial biogenesis via the stimulatory 
effect on Ying-Yang-1 (YY1) - PPAR- coactivator-1 (PGC1) transcriptional complex, 
involved in transactivation of mitochondrial genes and intensification of mitochondrial 
respiration[8]; (ii) direct effects on mitochondrial function potentially through interaction 
with regulatory mitochondrial proteins such as VDAC1 and Bcl-xL, which regulate 
mitochondrial substrate permeability and mitochondrial integrity[9]; (iii) activation of 
Hypoxia-Inducible Factor-1 (HIF1), composed of stable HIF1 and inducible HIF1 
subunit, the activator of the genes involved in glycolysis, glucose transport and 
mitochondrial respiration[12]. mTORC1 activates HIF1 via the upregulation of HIF1 
translation[13]. 
Another important function of TOR, critical for the control of metabolism and cell integrity, 
is the negative regulation of macroautophagy (therein called autophagy)[3, 5] (Fig.1). 
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Autophagy is the process of double membrane encapsulation and lysosomal degradation 
of cellular constituents such as organelles, protein aggregates, lipid droplets and portions 
of cytoplasm[14]. The process of autophagy involves a nucleation step via the formation of 
a preautophagosomal structure (PAT), continuing to the formation of phagophore and 
autophagosome vesicles. Finally, the autophagosome fuses with a lysosome allowing 
lysosomal degradation of the autophagosome content[14]. Autophagy plays three major 
roles in cells. Firstly, it provides energy through digestion of cellular constituents during 
starvation and other conditions affecting nutrient availability. This allows cells to survive 
nutrient limitations and autophagy might be vital for cell survival during stress such as 
ischemia. Secondly, autophagy regulates cell integrity by removing deposits and 
aggregates that affect normal cell physiology as well as damaged and malfunctioning 
organelles, which are the major source of oxidative stress[1]. In agreement, reactive oxygen 
species (ROS) produced by damaged mitochondria or through other mechanisms stimulate 
autophagy, results in suppression of oxidative stress[15]. Thirdly, completed autophagy 
might cause cell death, referred to as type II cell death, although the physiological 
relevance of this is unclear and disputable[16]. Autophagy is often associated with 
apoptosis and can be activated by many pro-apoptotic proteins such as p53 upregulated 
modulator of apoptosis (Puma) and Bcl-2–associated X (Bax) and inhibited by antiapoptotic 
proteins of the Bcl2 family[17-19]. In some cases, autophagy can be activated in response to 
pro-apoptotic stimuli as a potential pro-survival control mechanism or as a by-stander of 
the cell death associated with energy decline. In the other experimental settings, it was 
shown that autophagy mediated apoptosis in response to genotoxic stress[20]. 
Nevertheless, autophagy can modulate many effects of stress on cell viability and 
consequently, can be an important factor in anticancer treatment, which often involves 
extensive stress response[21].  
Hyperactivity of TORC1, which leads to dysregulation of metabolism and inhibition of 
autophagy, is associated with extensive ROS production[1, 15, 22]. ROS, not being properly 
decomposed, induces oxidative stress, the major source of cell damage such as DNA-
oxidation, lipid peroxidation and protein carbonylation. The accumulation of damage 
associated with oxidative stress is the driving force of aging, and, accordingly, TORC1 is the 
critical controller of aging in all eukaryotes from yeast to mammals[5, 6]. This data 
demonstrates that inhibition of TORC1 via mutagenesis or rapamycin treatment extends 
lifespan of yeast, worms, flies and mice [3, 23, 24]. Interestingly, two well-established 
mechanisms of lifespan extension such as caloric restriction and suppression of 
Insulin/Insulin growth factor-1(IGF1) -dependent signaling pathway control TORC1 
activity, indicating that TORC1 inhibition may be critical for lifespan extension and 
suppression of age-associated pathologies imposed by low-calorie diet and inhibition of 
Insulin/IGF1-regulated pathway[3]. 
Stimulation of metabolism, cell growth and ROS by mTORC1 contributes to different 
pathologies including carcinogenesis, and mTORC1 is often activated in human cancers[3]. 
Many tumor suppressors found inactivated in cancers such as Tuberoses Sclerosis -1 and -2 
(TSC1 and TSC2), liver kinase-B (LKB1), phosphatase and tensin homolog (PTEN), p53 and 
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neurofibromatosis type 1 (NF1) are inhibitors of mTORC1, while proto-oncogenes Ras, PI3K 
and AKT are mTORC1 activators[3, 5]. Obesity and type II diabetes are associated with 
chronic mTORC1 activation in metabolically active tissue, and mTORC1 impairs insulin 
sensitivity, stimulates hyperinsulemia and hyperglycemia[3, 5]. Obesity-associated 
mTORC1 activation also is a major risk factor for the development of nonalcoholic fatty liver 
disease (NAFLD), a risk factor of cirrhosis and hepatocellular carcinoma[3]. mTORC1 can 
also be involved in the pathogenesis of neurodegenerative disorders such as Parkinson-, 
Alzheimer-, Huntington- diseases, amyotrophic lateral sclerosis and frontotemporal 
dementia[3, 6]. All of these pathologies share similar etiology defined by the accumulation 
of toxic protein aggregates, which generate cellular damage, oxidative stress and cause cell 
death. These inclusions are cleared by autophagy, with mTORC1 potentially contributing to 
these syndromes via regulation of autophagy and protein synthesis, two processes affecting 
deposit accumulation[1, 3].  
mTORC1 activity is regulated by nutrients (the source of ATP), insulin and growth factors, 
and amino acids through small GTPases Ras homolog enriched in brain (Rheb) and the 
members of Ras-related GTP-binding (Rag) protein family RagA, RagB, RagC and RagD 
(Fig.1). Active GTP-bound Rheb directly interacts with mTORC1 and stimulates its activity 
through undefined mechanism. The members of Rag family control mTORC1 in a 
sophisticated manner, forming heterodimers between either RagA or RagB with either 
RagC and RagD. Interestingly, the RagA and RagB are active in GTP-bound form, whilst 
RagC and RagD are functional when loaded with GDP. [6]. According to a contemporary 
model, active Rag complexes directly interact with the mTORC1 subunit raptor directing 
mTORC1 into the surface of endosomes and late lysosomes, enabling its interaction with 
activated Rheb[6]. As Rags do not have any membrane-targeting signals, they are delivered 
to lysosomal surface by Ragulator protein complex, composed of p14, MAPK scaffold 
protein 1(MP1) and p18[6]. The activity or Rag proteins is regulated by amino acids with 
Rags being critical transducers of the activating signal from amino acids to mTORC1[3]. As 
described recently, Rag activation in response to amino acids is mediated by leucyl-tRNA 
synthetase, which binds Rag proteins and acts as GTPase-activating protein (GAP) for 
Rags[25]. The other proposed mechanisms of mTORC1 activation by amino acids involve 
mitogen-activated protein kinase kinase kinase (MAP4K3), inositol polyphosphate 
monokinase (IPMK) and mammalian vacuolar protein sorting 34 homolog (hVps34), 
belonging to class 3 PI3K[3, 26]. hVps34 is required for activation of phospholipase-D 
(PLD) in response to availability of amino acids. Amino acids induce interaction between 
phosphatidylinositol 3-phosphate and the Phox homology (PX) domain of PLD1, which 
causes PLD translocation to the lysosomal compartment, required for mTORC1 
activation[27]. 
Rheb GTPase is a critical regulator of mTORC1 in response to insulin, growth factors, 
energy and stress[1, 6]. Rheb is negatively controlled by the TSC1:TSC2 protein complex 
where TSC2 is GAP for Rheb, while TSC1 plays a supporting role stabilizing TSC2[28]. The 
TSC1:TSC2 complex integrates signals from different signaling pathways that positively or 
negatively modulate the TSC1:TSC2 activity [1]. Insulin and IGF1, the activators of cell 
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growth, stimulate mTORC1 via inhibitory phosphorylation of TSC2 by AKT[3]. 
Insulin/IGF1 stimulate Insulin/IGF1 receptor (In/IGF1R), which through the engagement of 
insulin receptor substrate-1 (IRS1) tethers and activates phosphatidylinositol-3-kinase 
(PI3K), which then converts phosphatidylinositol-4,5-biphosphates (PIP2) into 
phosphatidylinositol-3,4,5-triphosphates (PIP3). PIP3 induce AKT phosphorylation on 
Thr308 by phosphoinositide-dependent kinase-1 (PDK1) kinase recruiting both kinases to 
cytoplasmic membrane via their pleckstrin homology (PH) domains. PI3K also stimulates 
phosphorylation of AKT on Ser473 by mTORC2 which is required for full AKT 
activation[3, 7, 15]. The PI3K activity is counteracted by the tumor suppressor PTEN, which 
is a PIP3 phosphatase[3]. Activated AKT directly phosphorylates TSC2 on multiple sites, 
causing mTORC1 activation. In parallel AKT also stimulates mTORC1 via phosphorylation 
of mTORC1 interacting protein PRAS40, an inhibitor of mTORC1, and inhibitory 
phosphorylation of both TSC2 and PRAS40 cooperates in mTORC1 activation[3]. IGF1 also 
activates Ras GTPases, activating extracellular-signal-regulated kinase (ERK) and 
ribosomal S6 kinase (RSK1)[3]. Both ERK and RSK1 directly phosphorylate TSC2, which 
cause inhibition of its activity and TORC1 activation[3]. Inflammation, accompanied by 
production of pro-inflammatory cytokines such as tumor necrosis factor- (TNF), 
stimulates mTORC1 via IB kinase (IKK)-mediated phosphorylation of TSC1[3]. The 
canonical Wnt signaling pathway, the regulator of embriogeneis, provides another 
important mechanism of mTORC1 regulation. The Wnt pathway inhibits glycogen 
synthase kinase-3 (GSK3), which under normal conditions phosphorylates and activates 
TSC2[3] (Fig.1). 
2.2. AMPK 
While Insulin, growth factors and nutrients inhibit the TSC1:TSC2 complex and stimulate 
mTORC1, many stress insults have the opposite effect, activating TSC2 and inhibiting 
TORC1. Inhibition of mTORC1 under stress conditions allows cells to stop cell growth and 
proliferation in the unfavorable conditions switching to high-economy mode and 
supporting stress-relieving measures. Nutrient deficiency and many metabolic 
derangements cause an accumulation of AMP and ADP, which, in turn, activate AMPK. 
AMPK inhibits mTORC1 through phosphorylation of TSC2 and raptor[4]. Besides AMP 
accumulation, AMPK can be activated by different insults such as oxidative stress, DNA-
damage or the accumulation of Ca2+ potentially through an AMP-independent mechanism. 
Also some hormones such as leptin and adiponectin are able stimulate AMPK through 
mechanisms that are yet to be defined[4].  
AMPK is a protein complex composed of 3 subunits catalytical AMPKα, (encoded by 
AMPK1 and 2 genes scaffold AMPK subunit, (encoded by AMPK1 and 2 genes) and 
regulatory AMPK subunit, (encoded by AMPK1, 2 and 3 genes) in mammals. AMPK is 
activated via phosphorylation of AMPKa subunit on Thr172, although phosphorylation of 
other sites on AMPKα,  and  subunits are also involved in AMPK regulation[4]. The 
upstream AMPK kinase critical for AMPK activation in response to energy deficiency is 
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LKB1, which constantly phosphorylates AMPKα subunit on Thr172. The most established 
mechanism of AMPK activation involved binding AMP by AMPKg subunit which 
stimulates conformational changes in AMPKα subunit making it less accessible for AMPK 
phosphatases[4, 29]. Several protein phosphatases (PP) have been shown to be involved in 
the regulation of AMPK phosphorylation including PP2C[30], PP2A[31, 32], PPM1E[33], 
PP1[33, 34]. LKB activity can be stimulated by oxidative stress via the phosphorylation by 
ataxia telangiectasia mutated (ATM) kinase, leading to AMPK activation[35]. Other AMPK 
kinases shown to directly phosphorylate AMPK are Ca2+/Calmodulin-dependent protein 
kinase II (CaMKII), activated by accumulation of Ca2+ ions, and TAK kinase[36], activated in 
response to treatment with TNF-related apoptosis-inducing ligand (TRAIL) [37](Fig.1). 
Some proteins such as kinase repressor of Ras-2 (KSR2) can also regulate AMPK 
phosphorylation working as scaffold protein through regulation of access of either protein 
kinases or phosphatases to AMPKα subunit[38]. 
Activated AMPK phosphorylates many targets involved in the regulation of glucose 
metabolism: 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase 3 (PFKFB3), glycogen 
synthase-1 (GYS1), glutamine:fructose-6-phosphate amidotransferase (GFAT1), TBC1D1; 
lipid metabolism: acetyl- CoA Carboxylase-1 and -2 (ACC1 and ACC2), 3-hydroxy-3-
methylglutaryl-CoA reductase (HMGR), PLD1; polarity: cytoplasmic linker protein-170 
(CLIP170), golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 
(GBF1), kinesin light chain-2 (KLC2); transcription: (PGC1, sterol regulatory element-
binding protein-1 (SREBP1), FoxOs, Histone-2B, p300 and HDAC4,5,6; and mitosis: 
protein phosphatase-1 regulatory subunit 12C (PPP1R12C), p21-activated protein kinase 
(PAK2)[4, 39]. AMPK also contributes to mitochondrial function stimulating 
mitochondrial biogenesis via phosphorylation of PGC1 co-activator and regulating 
expression of mitochondrial genes[4]. AMPK regulates cell growth and autophagy in part, 
through TORC1 inhibition, although as shown recently AMPK can stimulate autophagy 
through direct phosphorylation of autophagy ULK1 protein. AMPK is also involved in the 
regulation of cell death in response to genotoxic stress, although the mechanisms are yet 
to be described[40-42]. 
Interestingly, lipid biosynthesis and autophagy controlled by mTORC1 via SREBP1 and 
ULK1, are under direct control by AMPK. AMPK directly phosphorylates and inhibit 
SREBP1 protein, suppressing lipogenesis[43]. AMPK also phosphorylates and activates 
ULK1 stimulating autophagy [44]. The redundancy of the mechanisms of regulation of lipid 
biosynthesis and autophagy though direct and indirect effects of AMPK demonstrates the 
critical role of AMPK in these processes and the importance of accurate regulation of these 
processes by mTORC1 and AMPK. 
The regulation of metabolism and autophagy by AMPK potentially contributes to lifespan 
regulation. Accordingly, the inactivation of one of the AMPK subunits (AMP-activated 
kinase-2 (AAK-2)) in Caenorhabditis elegans shortened lifespan by 12%, while animals with 
increased AAK-2 expression lived 13% longer than their wild type (WT) counterparts[45]. 
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The mechanism of life extension by AMPK involves CRTC-1 and FoxO transcriptional 
factors[46, 47]. Interestingly, the activity of AAK-2 is also required for protection against 
oxidative stress [48]. Similar results were obtained in Drosophila Melanogaster model, where 
the inhibition of drosophila AMPK shortened lifespan and increased susceptibility to 
oxidative stress and starvation[49] In accordance, gain-of-function LKB1 mutant extended 
lifespan in flies[50]. Although there is no such evidence for mammals, mammalian AMPK 
presumably plays a similar role in lifespan regulation. This idea is supported by the 
observation that AMPK activity is decreased in old animals potentiating the aging 
process[51]. 
Although the effects of AMPK on the lifespan regulation in mammals are not known, 
AMPK is involved in protection from different diseases[4, 52]. AMPKα2 subunit controls of 
glucose metabolism and AMPKα2 mice have pro-diabetic phenotype associated with 
diminished insulin secretion and glucose intolerance[53]. AMPK can also affect lifespan via 
the suppression of inflammation, a process associated with aging and many age-related 
diseases, including cancer[54]. Metformin, the most commonly prescribed anti-diabetic 
drug, activates AMPK and its activation is required for effect of metformin on glucose 
production in hepatocytes and, potentially, in glucose uptake in muscle[55]. Resveratrol, the 
plant-derived polifenol, which prolongs lifespan and improves health conditions of mice 
kept on high-calorie diet, also activates AMPK, which can potentiate the effects of 
resveratrol on health and aging [56].  
 
Figure 1. Regulation of the AMPK-mTORC1 axis and the role of mTORC1 in cellular processes. 
mTORC1 is activated by insulin and IGF1 via stimulation of the PI3K-AKT pathway, followed by 
inhibitory phosphorylation of TSC2 by AKT. The other signaling pathways stimulate mTORC1 through 
activation of ERK, RSK and IKK kinases in a TSC1:TSC2-dependent manner. TSC1:TSC2 inhibition 
leads to stimulation of Rheb, an activator of mTORC1. mTORC1 activation also required amino acids 
(AA) which stimulate mTORC1 via Rag complexes. Many stress insults activate AMPK which inhibits 
mTORC1 modulating many mTORC1-dependent processes such as metabolism, protein synthesis, cell 
growth and autophagy. 
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3. p53 and its role in aging and diseases 
Among the proteins involved in the lifespan regulation, the tumor suppressor p53 plays 
a central role. Originally identified as interactor of human polioma SV40 virus large T 
antigen, accumulated in transformed cells[57], it was proposed to be involved in cell 
transformation. Studies further demonstrated that p53 suppressed cell transformation 
and carcinogenesis[58]. Furthermore, p53 gene is mutated in more than 50% of human 
tumors, supporting the idea that p53 inactivation is a critical step in carcinogenesis[58]. 
The patients with Li-Fraumeni syndrome, characterized by predisposition to different 
form of cancer at early age, often carry a mutant p53 allele[58]. In the following study the 
tumor suppressive function of p53 was confirmed in mouse knockout model where p53-
deficeint mice developed cancers and chronic inflammation and the median of survival 
of p53-null mice is six months [59]. The extensive efforts to understand the function of 
p53 led to characterization of many p53 activities such as the regulation of genomic 
stability, control of cell cycle, induction cell death and senescence, and suppression of 
angiogenesis. All these mechanisms potentially contribute to tumor suppressive function 
of p53, although the mechanisms most critical for tumor suppression are yet to be 
defined[58]. 
The vast majority of processes controlled by p53 are exhibited through the regulation of 
gene expression. Being a transcription factor, p53 directly activates many genes involved in 
DNA repair such as growth arrest and DNA damage-45 (GADD45) and p53R2; cell cycle 
arrest and senescence: p21, 14-3-3and plasminogen activator inhibitor-1 (PAI-1); cell death: 
Bax, Puma, apoptosis inducing factor (AIF), Noxa; and inhibition of angiogenesis: 
trombospondin-1 (TSP-1)[60] (Fig.2). p53 activity is regulated through several mechanisms, 
many involving protein stabilization. p53 trancriptionally activates its negative regulators 
murine double minute 2 (MDM2), p53-induced protein with a RING-H2 domain (Pirh2) and 
constitutively photomorphogenic 1 (COP1), which bind and stimulate p53 degradation 
working as p53 E3-ubiquitine ligases[61].  
The elimination of damaged and modified cells, imposing the threat to the organism, is not 
the only strategy to fight cancer. It seems reasonable that many functions of p53 in the 
prevention of carcinogenesis operate via the regulation of metabolism and stress response. 
Not being properly controlled the derangements of these processes can lead to the 
accumulation of damage, the major source of mutations[15]. We have described that one of 
the mechanism involves the regulation of ROS, which being accumulated, might fuel 
mutagenesis and genomic instability[15]. ROS can also stimulate the cell cycle, migration 
and angiogenesis, so they can support initiation, promotion and progression of 
carcinogenesis[62]. Accordingly, our studies showed that inactivation of p53 via different 
mechanisms such as knockout, knockdown with shRNA, over-expression of Mdm2 or 
dominant-negative form of p53 led to ROS accumulation causing oxidative DNA-damage, 
increased rate of mutagenesis and genomic instability[62]. A xenograft study with lung 
adenocarcinoma A549 cells showed that p53 silencing accelerated tumor growth, and it was 
reverted by treatment with an antioxidant N-acetylcysteine (NAC)[62]. Moreover, p53-
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knockout mice, predisposed to carcinogenesis, were protected from the disease by NAC 
treatment and had significantly extended lifespan as compared to vehicle-treated 
controls[62]. A number of p53 targets with antioxidant activities including Sestrins, 
glutathione peroxidase 1 (GPx1), manganese superoxide dismutase (MnSOD), catalase, 
aldehyde dehydrogenase 2 (ALDH1), gutaminase 2 (GLT2) and p53-induced nuclear protein 
1(INP1)[1, 15] were identified (Fig.2).  
Some of the p53-inducible proteins such as TP53-induced glycolysis and apoptosis regulator 
(TIGAR), an inhibitor of glycolysis, regulate ROS via control of metabolism. TIGAR lowers 
the fructose-2,6-bisphosphate levels and suppresses activity of phosphofructokinase-1 
(PFK1) [63]. It can lead to the re-direction of glycolytic intermediates into the pentose 
phosphate pathway providing cells with NADPH, the important reducing equivalent for 
antioxidant reactions in the cell[64]. p53 also coordinates bioenergetic processes such as 
mitochondrial function regulating mitochondrial respiration via activation of cytochrome C 
oxidase 2 (SCO2), regulator of complex IV, subunit I of complex IV and apoptosis inducing 
factor 1 (AIF)[64]. In addition Parkin (PARK2), a gene associated with Parkinson disease, is a 
p53 target, inactivation of which leads to enhancement of glycolysis, suppression of 
mitochondrial respiration and ROS accumulation[65]. As a result, p53 may control different 
metabolic pathway involved in ROS production. On the contrary when stress is too high 
and damages are irreparable, imposing the threat of mutations and genomic instability, p53 
induces ROS production through up-regulation of proapoptotic genes Puma, Bax and PIG3, 
facilitating cell disorganisation during apoptosis[62, 66] (Fig.2). 
The protective effects of p53 can also be mediated by regulation of the AMPK-mTORC1 
axis[15]. Elevated activity of mTORC1 is associated with the accumulation of damage and 
oxidative stress[15, 67], resulting in exacerbated aging and imposing health risks. 
Overactivation of mTORC1 might be even more detrimental under stress conditions such as 
genotoxic stress, when the anabolic and catabolic processes should be coordinated to enable 
the repair and elimination of the damage. Accordingly, it was shown that p53, activated by 
DNA-damage and via other mechanisms, inhibited mTORC1 and mTORC1-dependent 
translation[68, 69]. p53 inhibits mTORC1 through activation of genes involved in negative 
regulation of mTORC1, such as a suppressor of insulin signaling insulin-like growth factor 
binding protein 3 (IGF-BP3), PTEN, TSC2, AMPKb1, Sestrin1 (Sesn1) and Sestrin2 
(Sesn2)[15]. mTORC1 inhibition by p53 is also mediated by stimulation of AMPK 
phosphorylation on Thr172[70]. The other potential mechanism involves the clearance of 
epithelial growth factor receptor, the activator of PI3K-AKT-mTORC1 pathway from the 
surface, disabling the signaling from the receptor[71, 72].  
Autophagy is another mechanism imposed by p53 to protect cells from the accumulation of 
damage [71] (Fig.2). p53 activates autophagy via transcriptional activation of genes 
involved in the regulation of the AMPK-mTORC1 pathway[70, 73], although other p53 
targets are directly involved in the autophagic process or operate through other 
mechanisms. The list of pro-autophagic genes regulated by p53 includes lysosomal protein 
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damage-regulated autophagy modulator (DRAM), ULK1[74], p53INP1 (which interacts 
with ATG8 and promote autophagic cell death)[75], Bax, Puma[18] and a new gene with 
unknown function ISG20L1[76]. Interestingly that autophagy also contributes to p53-
induced cell death, potentially providing the ground for elimination of damaged cells, if 
they are irreparable. The cytoplasmic form of p53 can negatively regulate autophagy, 
counteracting the effects of the nuclear form of p53[77]. This potential mechanism involves 
interaction with components of autophagic machinery, such as family kinase interacting 
protein 200 (FIP200/ATG17)[78].  
The effects of p53 on the control of stress response, metabolism, ROS and autophagy 
connect p53 with the lifespan regulation and longevity. p53 knockout mice develop cancer 
and die by the age of 6 months, indicating a critical role of p53 in the lifespan regulation 
through suppression of carcinogenesis[59]. Nevertheless, this model precluded 
characterization of the role of p53 in aging and longevity. To study the effects of p53 on 
aging several models were established and these models show different, sometimes 
contradicting, phenotypes.  
In the first model, mice expressed a truncated p53 lacking exons 1-6 (called m allele in 
p53+/m mice). The p53m locus produced a 24K C-terminal part of the p53 protein[79]. 
Interestingly, these mice demonstrated 23% reduction in median of longevity. Although 
young (3-12 months old) mice did not show any difference compared with WT mice, 
after 18 months p53+/m mice revealed exacerbated aging-related phenotype exhibiting 
weight loss, lordokyphosis, and an absence of vigor[79]. Tissue analysis demonstrated a 
decrease in muscle and adipose tissue as well as reduced kidney, liver, spleen and testes 
mass, typical features of aging. Also, mice showed thickness in both bone density and 
dermal thickness, and defects in wound healing. Moreover, the mice had reduced 
survival in response to stress[79]. Surprisingly the frequency of many other pathologies 
associated with aging including liver diseases, brain atrophy, hair graying and alopecia, 
skin ulceration, amyloidal deposits and cataract were not increased in this  
model[79]. The feature reported in the p53+/m mice was a decreased predisposition to 
cancer[79]. 
As reported in another study, mice with increased levels of expression of natural N-
terminally truncated p53 (p44) had an accelerated aging phenotype, deteriorated health and 
decreased lifespan, characterized by defects in fertility linked with testicular degeneration, 
lordokyphosis and decrease in bone density, cognitive decline and synaptic deficit early in 
life[80, 81]. These mice demonstrated overactivated IGF1R signaling and many phenotypes 
were rescued by IGF1R heterozygosity. p44 also exacerbated a neurodegenerative 
phenotype in the mouse model of Alzheimer’s disease based on the overexpression of 
human amyloid precursor protein (APP), where p44 facilitated degeneration of memory-
forming and memory retrieving areas of the brain[81].  
A common phenotype observed in these two models is accelerated aging and decreased 
susceptibility to carcinogenesis[79, 80]. As it was suggested, p53 is overactivated by short 
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form and stimulated an aging phenotype, it also provided better protection from cancer[79, 
80]. An alternative explanation of the effects of truncated p53 on lifespan and aging involves 
suppression of many p53 activities and downregulation of some critical genes involved in 
the stress response and metabolism, resulting in an effect on viability, although the 
expression of some p53 targets was still retained and even increased. Both artificial 24K, and 
natural p44 forms of p53 lack transactivation domains, which are required for the most of 
p53 activities including tumor suppression[82]. Both truncated forms bind full-size p53 and 
counteract many of its activities similar to the effects of N-terminally truncated forms of the 
other p53 family members p63 and p73 on full size proteins[83]. Accordingly, 
overexpression of p44 causes accumulation of p53 and disability of full-size p53 to 
transactivate most of its targets[80, 84, 85]. The truncated p53 retains a full form in 
cytoplasm, inhibiting the p53 nuclear function [86]. Also, an inhibitory effect of truncated 
p53 is evident as p44 may be selected in human cancers, supporting carcinogenesis[87]. 
Thus truncated p53 might compromise p53 activities rather than enhance them. 
Simultaneously, some p53 functions, for example those involved in ROS production and 
senescence, might be intact or even increased causing accelerated aging phenotype. A more 
widespread analysis of p53 targets is required in these models to better understand the 
impact of truncated p53 in this phenotype. 
Other models indicate that tumor suppressive and aging-regulatory functions of p53-
dependent might be separated. In one model, a genomic segment containing whole p53 
gene was integrated in the mouse genome (p53Tg mice). These mice exhibited increased 
p53 response to DNA-damage and were able to rescue the cancer-prone phenotype of 
p53-deficient mice. The p53Tg mice were resistant to carcinogenesis, but in contrast to 
previous models, they did not reveal any signs of accelerated aging. Interestingly, a 
similar phenotype was observed with Mdm2 hipomorphic (haploinsufficient) mice, 
characterized by increased p53 activity, which were cancer resistant but aged 
normally[88, 89].  
MDM2 binds p53 and stimulates protein degradation, inhibiting p53 activity. The Arf 
tumor suppressor, a product of the INK4A locus, stimulates p53 activity antagonizing 
MDM2-dependent degradation. Transgenic mice with an extra copy of the Arf gene, along 
with an extra-copy of p53 gene (super-Arf/p53 (s-Arf/p53) mice) demonstrated increased 
activity of p53 and enhanced expression of p53-dependent p21 and antioxidant Sesn1 and 
Sesn2 genes. These mice were resistant to cancer, similar to the p53Tg mice, and 
fibroblasts from s-Arf/p53 mice were resistant to immortalization and transformation, 
implying low susceptibility of these mice to carcinogenesis. In contrast to previous 
models, these mice had an extended average lifespan of 16% and show signs of delayed 
aging as evident by the test on neuromuscular coordination (tightrope success test) and 
hair re-growth test. Aging is associated with the accumulation of DNA-damage and 
oxidative stress, and s-Arf/p53 mice exhibited decreased levels of DNA damage as 
illustrated by H2AX staining and decreased oxidative stress evident from analysis of ROS 
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in splenocytes, decreased lipid peroxidation and low abundance of carbonylated proteins 
in liver. The s-Arf/p53 mice were also resistant to oxidative stress, emphasizing the 
potential role of the mechanisms of stress response in suppression of aging and 
carcinogenesis[90]. This data is in concordance with previous observations that showed 
that inactivation of p53 or its upstream regulator ATM decreased lifespan and caused 
accumulation of oxidative damage in mice[62, 91]. Both p53- and ATM-null mouse strains 
were predisposed to cancer, and these phenotypes were prevented by antioxidant NAC 
treatment[62, 92]. Interestingly, the activity of p53 is decreased with age supporting a 
concept that p53 might be an important anti-aging factor[93]. 
Suppression of carcinogenesis was not the primary function of p53 in evolution as p53 is 
found in the organisms, such as Caenorhabditis elegans and Drosophila Melanogaster, which do 
not develop cancer. In the Drosophila model, overexpression of p53 in adult flies increased 
the lifespan of males, but limited lifespan in female flies. Also, the moderate overexpression 
of p53 during larvae stage extended lifespan in both male and female flies. p53-deficient flies 
were sick and had a decreased lifespan[94]. It is possible that p53 controls the accumulation 
of damages as well as other functions. Interestingly, the overexpression of dominant-
negative form of p53 in flies brain extended their lifespan [94]. This data suggests that p53 
can play an opposite role in lifespan regulation and aging in the peripheral organs and in 
the brain, where it can potentiate hormone production or other processes affecting aging. 
p53 can also regulate hermesis in response to -irradiation[95] and, moreover, p53 also 
potentiates life extension in response to the mitochondrial stress associated with 
downregulation of mitochondrial genes[96]. Accordingly, it was reported that the positive 
and negative effects of p53 on lifespan was dependent on the level of mitochondrial 
bioenergetic stress[97]. 
 
Figure 2. Tumor-suppressor p53 regulates lifespan and suppresses age-related diseases. p53 is 
activated in response to different stress insults and dependent on the stress intensity triggers different 
sets of genes either supporting pro-survival or cell death programs. p53 can support longevity and 
suppress age-related diseases via regulation of DNA-repair, cell cycle, metabolism and antioxidant 
response. Otherwise p53 eliminates damaged and potentially dangerous cells through activation of 
apoptosis or senescence, suppressing carcinogenesis. 
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4. Role of FoxO family in cellular processes and longevity 
Another group of proteins playing a critical role in the lifespan regulation and aging are the 
transcription factors of the FoxO family. Analysis of Caenorhabditis elegans mutants, which 
extended lifespan of the worms, led to the identification of DAF2 and AGE1 genes, the 
orthologues of the mammalian In/IGF1R and PI3K genes respectively. Simultaneous 
inactivation of DAF16 suppressed extended lifespan phenotype of the DAF2- and AGE1- 
mutants providing a link between DAF2, AGE1 and DAF16. There is only one FoxO gene in 
invertebrate genome (DAF16 in Caenorhabditis elegans; dFoxO in Drosophila Melanogaster) 
while a mammalian genome is composed of four members FoxO1, FoxO3A, FoxO4 and 
FoxO6[98]. In spite of high sequence similarity and recognition similar sequences in the 
promoters of target genes, the mammalian FoxO family members have different tissue-
specific expression and potentially different, although overlapping, functions in the 
organism. According to knockout studies, inactivation of FoxO1 is embryonically lethal due 
to insufficient vascularisation of the embryo. FoxO3A-deficient animals are viable, although 
demonstrate defects in ovarian follicle activation, while FoxO4-deficient animals are viable 
with no significant abnormalities[98].  
Insulin/IGF1 signaling inhibits FoxO via activation of the PI3K-AKT pathway(Fig.3), 
followed by phosphorylation the FoxO proteins by AKT on highly conserved residues. AKT 
phosphorylation makes FoxOs susceptible for interaction with 14-3-3 proteins, which bind 
and retain FoxOs in the cytoplasm masking their nuclear localization signal[98]. Thus, AKT 
phosphorylation invalidates the transcriptional activity of FoxOs, inhibiting FoxO-
dependent processes. On the contrary, FoxO can be phosphorylated and activated by Jun N-
terminus kinase (JNK) and STE20-like protein kinase 1 (MST1). JNK and MST1 can be 
activated by different stress insults, most evidently oxidative stress, with activating 
phosphorylation of FoxOs by JNK and MST1 having predominate inhibitory effects of 
AKT[98, 99]. Strikingly, prolonged activation of In/IGF1R stimulates ROS production, which 
leads to JNK activation followed by FoxO phosphorylation and nuclear translocation, 
counteracting effects of AKT on FoxO suppression. Similar to FoxOs, JNK is an important 
regulator of longevity[100], extending lifespan in worms and flies by suppressing 
Insulin/IGF1 signaling pathway [101, 102].  
FoxOs impinge on the control of lifespan potentially via transcriptional regulation of genes 
involved in the stress-response, although the critical targets involved in this process are 
unknown. Potential candidates are ROS scavengers, such as: MnSOD, Catalase and 
peroxiredoxin3 (Prx3); regulators of protein synthesis, such as: 4EBP1 and regulators of 
autophagy, including BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), 
LC3 and Garabl12[98]. Interestingly, FoxO can also stimulate autophagy through a 
mechanism independent of its transcriptional activity[103]. Besides the activation of stress-
relieving pathways, FoxOs also inhibit cell cycle though several mechanisms, such as 
activation of cell cycle inhibitors p27 and p21, and suppression of cell cycle regulators c-Myc 
and cyclin D[98, 99]. Accordingly, overexpression of FoxO3A causes G2-M delay in 
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fibroblasts[98]. Regulation of the cell cycle by FoxOs might be important for stress-relieving 
mechanisms, as cells need to restrain proliferation in order to restore homeostasis and avoid 
accumulation of damages[98]. 
The activities of FoxOs are not limited to the activation of stress-relieving and pro-survival 
pathways. FoxOs also activate the expression of proapoptotic proteins Bim, Puma, Fas 
ligand (FasL) and TRAIL and stimulate cell death under certain conditions[98]. The exact 
mechanism that discriminates between pro-survival and pro-death programs regulated by 
FoxOs are unknown, the outcome of FoxOs activation might be dependent on severity of 
stress and cell type.  
The regulation of pro-survival stress-relieving genes and pro-apoptotic genes by FoxOs is 
reminiscent of the effects p53 on cell homeostasis, which protects under low stress 
conditions and induces cell death when stress is too strong and causes accumulation of 
damages within the cell[15]. Strikingly, FoxOs and p53 are able to activate the same targets 
including MnSOD, catalase, Sesn1, p21 and Puma[15, 98]. It is possible that there is some 
functional redundancy in the regulation of stress response by p53 and FoxO proteins, 
ensuring the proper outcome should one of the pathways be disabled. Interestingly, p53 and 
FoxOs are under mutual regulation. p53 positively regulate FoxO3A via transcriptional 
activation of FoxO3A gene[104], although p53 also stimulates expression of MDM2, which is 
involved in FoxO ubiquitination and degradation[105]. Surprisingly, in response to DNA-
damage p53 can inhibit FoxO3A via SGK1 kinase activation and subsequent FoxO3A 
retention in cytoplasm[106]. FoxOs can also regulate p53 in a positive or negative manner. 
FoxOs stimulate activity of AKT, which negatively regulates p53 via phosphorylation of 
MDM2[99]. FoxO3A can also impair p53 transactivational function, although can positively 
regulate p53-dependent cell death in serum starved cells[107]. Otherwise, FoxO3A directly 
interacts with the ATM kinase, upstream p53 activator, and stimulates ATM 
phosphorylation on Ser1981, regulating DNA-damage response which might be involved in 
p53 activation[108]. FoxOs can also upregulate p53 via activation of upstream p53 regulator 
Arf[109]. This complicated picture illustrates that there is a communication between p53 and 
FoxOs providing the mutual control of activity determining cell fate (Fig.3). 
The antioxidant function of FoxOs is especially important for control of stem cell 
maintenance. The mice with simultaneous inactivation of FoxO1, FoxO3A and FoxO4 in 
hematopoietic system had diminished number of hematopoietic stem cells (HSC) in bone 
marrow, paralleling expansion of myeloid progenitor cells in the blood. FoxO-deficient HSC 
had elevated levels of ROS in comparison to WT control and have strong defects in the 
ability to restore hematopoietic system of recipient mice, indicating the critical role of FoxO 
in self-renewal of stem cells. These defects were rescued by treatment with antioxidant 
NAC, confirming the critical role of FoxO in the regulation of HSC ROS, which is important 
for regulation of HSC quiescence and regenerating ability[98]. 
Another function of FoxOs is the control of metabolism. FoxO1 is highly expressed in 
insulin-responsive tissues and regulates glucose and lipid metabolism, ensuing adaptation 
to different feeding conditions. In response to the decrease of insulin levels, FoxO1 
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intensified gluconeogenesis in the liver through regulation of glucose-6-phosphatase 
(G6Pase) and phosphoenolpyruvate carboxykinase (PEPK). FoxO1 also stimulated 
transcriptional co-activator PGC1 and synergizes with PGC1 for G6Pase transactivation. 
The activation of G6Pase and PEPK ensures stable blood glucose levels in fast conditions. 
FoxO1 also regulates lipid metabolism via activation of an inhibitor of lipoprotein lipase 
apoliprotein (ApoCIII), which is involved in hypertrigyceridemia development in diabetic 
patients[98].  
 
Figure 3. Stress and the insulin/IGF1-PI3K-AKT pathway control cellular processes through 
regulation of FoxOs. While many stress insults activate FoxOs, the Insulin/IGF1-PI3K-AKT inhibits 
their activity. Thus FoxO factors integrate the information from different signaling pathways and 
control the expression of genes involved in regulation of cell proliferation and viability, autophagy, 
metabolism and cell death. As a result they contribute to regulation of longevity by FoxOs. 
The regulation of genes involved in glucose and lipid metabolism underlines the potential 
role of FoxOs in diabetes which might work in a protective fashion or exacerbate the 
diabetic phenotype. Insulin resistance and glucose intolerance, the hallmark of type II 
diabetes, are characterized by the suppression of the PI3K-AKT signaling pathway [110]. 
This might be due to the elevated activity of mTORC1 which phosphorylates and regulates 
IRS1 and Grb10 proteins[3]. IRS1 transduces signals from In/IGF1R toward PI3K and its 
phosphorylation by mTORC1-dependent p70S6K causes its degradation. Grb10 negatively 
regulates growth factor signaling through binding of IGF1R and its phosphorylation by 
mTORC1 stabilizes and activates Grb10[111, 112]. FoxOs can modulate insulin signaling 
through AMPK activation and TORC1 inhibition as well as via transcriptional activation of 
IRS2, PI3K (p110a) and InR [99] and the activation of these proteins potentially support 
insulin sensitivity. FoxOs also activate rictor, the critical component of TORC2 complex 
required for phosphorylation and full activation of AKT [7, 99]. In contrast, the diabetic 
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phenotype caused by InR deficiency was rescued by FoxO1 heterozygosity, where deletion 
of one FoxO1 allele restored insulin sensitivity[98], indicating that tight control of FoxO 
activity was required for proper protective function of FoxO factors. 
5. Identification and characterization of Sestrins 
Sestrins are highly conserved gene gamily found in all multicellular organisms of the 
animal kingdom. The invertebrate genome contains one Sestrin (Sesn) gene while there are 
three genes in vertebrates Sesn1, Sesn2 and Sesn3[15]. Sesn1, originally named p53-
activated gene #26 (PA26), was identified as a p53-inducibe gene in a screening where p53 
was induced in a tetracycline–dependent manner[113]. The human SESN1 gene is found in 
6q21 position[114] and is transcribed into three different mRNA translated into proteins 
with Mw~46, 55 and 68kD[114]. The Sesn1 mRNAs are transcribed from 3 promoters using 
an alternative first exon (Exon 1,2 or 3), which is spliced with the common exon 4[114]. All 
protein products of SESN1 share the same C-terminal part encoded by exons 4-10. Among 
the three transcripts only short transcripts 2 and 3 are induced by p53, while transcript 1 is 
constantly expressed regardless of p53 status[114]. The gene is ubiquitously expressed in 
all tissues, although at different levels and predominantly in the pancreas, kidney, skeletal 
muscle, lung, placenta, brain, ovary and testis[114]. Sesn1 is a stress-responsive gene 
activated in response to genotoxic stress imposed by -irradiation, UV-light and 
doxorubicin treatment in a p53-dependent manner[114]. Sesn1 is induced with kinetics 
similar to the “classical” p53-inducible genes MDM2 and p21, indicating that this is a direct 
p53 target[114]. p53-responsive elements were identified within intron 1[115] and intron 
2[114] of the Sesn1 gene, although the exact role of either of these elements in Sesn1 
activation by p53 in vivo requires additional analysis. Besides genotoxic stress, Sesn1 is also 
activated in response to serum withdrawal[114], indicating the regulation by a 
transcription factor(s), which are under control by growth factors. Among them, FoxOs are 
the most prominent candidates, which expression is negatively regulated by insulin and 
IGF1 through activation of the PI3K-AKT signaling pathway followed by inhibitory 
phosphorylation of FoxOs by AKT[98, 99]. Accordingly, Sesn1 was identified by 
microarray analysis and real time PCR as a gene activated by FoxO3A[116] and FoxO1[117, 
118] (Fig.4).  
Sesn2 was identified by microarray analysis as a gene activated by severe hypoxia in 
glioblastoma A172 cells [119]. The human SESN2 gene is located in position of 1p35.3[119] 
and is transcribed into one mRNA that encodes a polypeptide with Mw~60 kDa[119]. 
Similar to Sesn1, Sesn2 is expressed in all tissues, but predominantly in the placenta, lung, 
liver, kidney, pancreas, testis and leucocytes (AVB and Chumakov PM, unpublished). 
Besides hypoxia, Sesn2 is activated in response to many stress insults including oxidative 
stress, DNA-damage and metabolic derangements[119]. In spite of the important role of 
HIF1 in the regulation of hypoxia-inducible genes, activation of Sesn2 by hypoxia was not 
dependent on HIF1[119]. This is supported by several observations: (i) the kinetics of Sesn2 
induction is significantly delayed compared to typical HIF1-dependent genes such as VEGF 
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and RTP801, but similar to induction of HIF1-independent GADD153 gene; (ii) no HIF1-
binding sites were found in the promoter or introns of the Sesn2 gene[119]; (iii) Sesn2 was 
induced in response to hypoxia mimetic deferoxamine mesylate in HIF1a-proficient but not 
HIF1-deficient immortalized astrocytes (ABV, unpublished). Nevertheless, HIF1 can 
contribute to Sesn2 expression under some conditions. Thus it was showed that HIF1 
protected airway epithelium against oxidative stress potentially via the activation of 
Sesn2[120]. Sesn2 is also activated by NO and hypoxia in a HIF1-dependent manner in 
macrophages[121], so it is possible that HIF1 plays a role in Sesn2 regulation in tissue-
specific manner. Genotoxic stress imposed by -irradiation, UV light, doxorubicin, etoposide 
and camptothecin induces Sesn2 expression in a p53-dependent manner[119, 122]. The 
activation of two of the three members of Sestrin family by p53 indicates the importance of 
Sestrins in p53-dependent processes. The p53-binding site was identified by chromatin 
immunoprecipitation (ChIP) with the paired-end ditag (PET) sequencing strategy in the 
region 9.6 kb downstream of SESN2 gene[115]. Oxidative stress activates Sesn2 in a p53-
independent manner, although p53, which is also activated by oxidative stress, contributes 
to transactivation of Sesn2[123]. The mechanism of Sesn2 activation in response to oxidative 
burst induced by NMDA receptor is described in neurons, where Sesn2 induction is 
mediated by C/EBP transcription factor via –378 to –249 and –249 to –107 regions in SESN2 
promoter[124] (Fig.4A).  
Another mechanism of Sesn2 regulation involves nerve growth factor-induced-B 
member Nur77 (NGFI-B/TR3), an orphan nuclear receptor expressed in multiple 
tissues[125]. Two Nur77 activators 1,1-Bis(3'-indolyl)-1-(p-methoxyphenyl)-methane 
(DIM-C-pPhOCH3) and 1,1-bis(3'-indolyl)-1-(p-phenyl)methane (DIM-C-pPhOH) 
induce Sesn2 and activation of Sesn2 in response to these compounds is inhibited by 
shRNA against Nur77[125]. Stimulated Nur77 inhibits cell proliferation and induces cell 
death. Moreover treatment with Nur77 activator DIM-C-pPhOCH3 suppressed growth 
of human bladder cancer cell line KU7, suggesting the impact of Sesn2 and several other 
genes co-activated with Sesn2 in suppression of tumor growth and tumor cells’ viability 
[125]. Accordingly we showed that Sesn2 suppressed colony-formation in  
different cancer cell lines originated from lung, colon, breast and kidney tumors[119] 
(Fig.4A).  
Other stimuli activate Sesn2 via a yet to be defined mechanisms. Sesn2 is activated in 
response to expression of HIV Tat protein in the brain potentially through induction of 
inflammation and oxidative stress[126]. Accordingly Sesn2 is also activated in response to 
-amyloid peptides associated with oxidative stress in neurons[127]. Impact inflammation 
in Sesn2 expression might be mediated by NO-production, and accordingly NO is the 
Sesn2 activator[128]. Sesn2 is also activated in the brain of Securin-deficient mice[129]. 
Securin is a protein, which in complex with Separase, regulates chromosomal separation 
and metaphase-anaphase transition[129]. Securin deficiency causes genomic instability 
and might regulate Sesn2 via p53 activation. Sesn2 transcriptional activity is also 
regulated by the mechanisms involved acetylation/deacetylation of histones, which can be 
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controlled by oxidative stress and other stimuli[130]. In accordance, treatment with the 
histone deacetylase inhibitor trichostatin A (TSA) induces Sesn2 expression in 
neurons[130]. 
Sesn2 modulates cell viability in response to stress, aggravating cell death in response to 
DNA-damage, induced by UV light and doxorubicin, and serum starvation but supporting 
cell viability in conditions of H2O2 treatment and hypoxia[119]. It might play an important 
role in tissue protection in response to ischemia/hypoxia and some other stress insults. 
According to our data, Sesn2 is activated in the brain in a model of acute ischemia induced 
by acute hypoxia in a model of stroke, created in rats by permanent middle cerebral artery 
occlusion (MCAO)[119].  
Sesn3 was originally identified in silico via search of databases for the sequences sharing 
homology with the Sesn1 and Sesn2 genes[119, 131]. The human SESN3 gene is located in 
position 11q21[119] and is transcribed into 2 mRNA which translated into proteins with 
Mw~53kDa and ~44kDa, lacking 72 AA at N-terminal part[118]. Similar to other Sestrins, 
Sesn3 is expressed in all tissues, and increased levels of expression are observed in skeletal 
muscle, placenta, small intestine, leucocytes, kidney, colon and brain[131]. Sesn3 was 
identified as a direct target of FoxO3A and FoxO1 transcription factors [117, 118]. FoxO1 
directly activates Sesn3 via binding of a 250bp region within 1st intron of human and mouse 
SESN3 gene[118] (Fig.4A).  
Protein products of Sesrin genes from different organisms display the highest similarity 
with Sesn1. According to prediction by GLOBE, (http://cubic.bioc.colum-
bia.edu/predictprotein) Sestrins are compact globular domain proteins composed of -
helical regions. Three of these -helical regions which include helices 3-8, 9-10, and 
11-16 are highly conserved among Sestrins and are separated by less conserved hinge 
regions. According to ProSite analysis (http://www.expasy.ch/prosite) Sestrins contain 
several Ser/Thr and Tyr phosphorylation sites, mainly located in -helical regions, 
including CK2 phosphorylation sites in 8 and 10, three PKC sites in 11, 15 and 16, 
one cAMP/cGMP-dependent protein kinase phosphorylation site in 10 and one tyrosine 
phosphorylation site within helix 14. There are also 13 potential tyrosine residues within 
helices 11-16, which can be phosphorylated by Tyr kinases[119]. Although these 
predictions require verification, phosphorylation of several residues was demonstrated in 
high-throughput screenings, thus S352 of Sesn1 is phosphorylated by ATM kinase, 
implying the role of Sesn1 in DNA-damage response and metabolism[132]. According to 
phosphopeptyde database (http://www.phosphosite.org) Sesn2 phosphorylations on 
Tyr342 and Tyr356 were found in acute myelogenous leukemia indicating involvement of 
Sesn2 in tyrosine-kinase signaling. 
Efforts to characterize Sestrins in the other organisms led to the identification of Sesn1 gene 
in Xenopus Laevis[133]. Although no function was assigned, it was showed that Sesn1 was 
accumulated in notochord at the onset of neurolation[133]. The reciprocal translocation 
(6;18)(q21;q21) observed in heterotaxia (abnormal organs arrangement in the body) patients 
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revealed breakpoint region within 1st intron of Sesn1 gene, which led to propose that Sesn1 
might be responsible for the heterotaxia phenotype[131]. These observations were followed 
by analysis of zebrafish model. Knockdown of Sesn1 in the zebrafish caused lateral 
disturbances in the heart and gut, providing evidence for a potential role of Sesn1 in the 
regulation of left-right asymmetry via Nodal signaling pathway[134]. Interestingly, Nodal 
auto-activation is mediated by a forkhead transcription factor FoxH1 (known as Sur in 
zebrafish) and Sesn1 is able to interact with FoxH1 in vitro[134].  
To gain insight into the physiological function of Sestrins we studied the functions of 
drosophila (d) Sesn (dSesn) in fly model[135]. The analysis of expression has been shown 
that the dSesn expression is increased in adult flies in comparison to larvae stage, and 
dSesn is highly expressed in thoracic muscle (analog of skeletal muscle in 
mammals)[135]. Interestingly, dSesn expression in fly muscles recapitulates the high 
expression level of the members of the Sestrin family in skeletal muscles in 
mammals[114, 119, 131]. Overexpression of dSesn in the dorsal wing region produces a 
bent up wing phenotype and Sesn2 activation in the eyes diminishes the eye size. Both 
phenotypes were evoked by decreased cell size, while dSesn overexpression did not 
affect cell number[135]. Knockout of dSesn do not seem to cause any developmental 
problems indicating no role of dSesn in morphogenesis. Nevertheless, the adult flies 
accumulated many age related defects, suggesting a role of Sentrins in the regulation of 
aging (see below)[135]. Interestingly, similar to mammalian Sestrins, dSesn is also under 
control of p53 and FoxO, although dFoxO appeared to be the predominant 
transcriptional activator of dSesn[135] (Fig.4B). 
 
Figure 4. Regulation of Sestrins’ expression. (A) Different stress insults regulate Sestrin genes via 
activation of p53, FoxOs, C/EBP and some other transcriptional factors in mammals. On the contrary 
AKT activated in response to insulin/IGF1 pathway or Ras can suppress activity of FoxOs. (B) Similar to 
mammals, drosophila (d) Sesn is activated by dp53 and dFoxO. Prolonged stimulation of InR stimulates 
dSesn expression through the TORC1-JNK-dFoxO axis, counteracting an inhibitory effect of AKT 
activation. 
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6. Antioxidant function of Sestrins 
Identification of Sestrin gene family did not provide any clues toward their functions due 
to low similarity with any other proteins [1]. To better understand Sestrins’ function, an 
iterative analysis of Sesn2 protein sequence using PSI-BLAST and structural analysis 
using 3D-PSSM programs were performed. We have observed that a fragment of protein 
around 75 amino acids in length (corresponding to region amino acids 100-175 of Sesn2) 
shares sequence and structural homology with Mycobacterial Tuberculosis AhpD protein 
and other related proteins[123]. The homology spans 5 a-helices of conserved region of 
Sestrins and C-terminal a-helical portion of AhpD[123]. Interestingly, some AhpD family 
members, such as caroboxymuconolactone decarboxylases, consist of this domain only. 
AhpD is a critical component Mycobacterium tuberculosis hidroperoxide reductase 
responsible for regeneration of bacterial peroxiredoxin AhpC, which is oxidized during 
reduction and decomposition of ROS or reactive nitrogen species (RNS). Peroxiredoxins 
are thiol-containing peroxidases conserved among prokaryotes and eukaryotes which 
catalytical center contains 2 conserved cysteines, one is a peroxidatic cysteine oxidized to 
SOH group during reaction with peroxides, and the other is resolving cysteine which 
forms disulfide bridge with catalytical cysteine. Oxidized cysteines are regenerated by 
AhpD in Mycobacterium tuberculosis or the thioredoxin/thioredoxin-reductase (Trx/TrxR) 
system in eukaryotes[15, 136]. AhpD contains two critical cysteines, whereas only one of 
them is conserved in Sestrins[123]. The major difference between prokaryotic and 
eukaryotic peroxiredoxins is that reactive cysteine of eukaryotic peroxiredoxins can be 
easily overoxidized to cysteine sulphinic acid (-SO2H) or sulphonic acid (-SO3H) forms 
and special enzymatic system is required for the regeneration of the overoxidized 
cysteine[136].  
The homology between Sestrins and AhpD indicates that Sestrins might be antioxidant 
proteins regulating mammalian peroxiredoxins. Accordingly, Sesn1- or Sesn2-silenced cells 
have elevated ROS levels and exhibit oxidative stress as supported by elevated levels of 
DNA-oxidation and increased mutagenesis[62, 123]. Sesn1- and Sesn2-silenced cells also 
have higher RNS levels comparatively to control implying the role of Sestrins in RNS 
metabolism as well. Complementary experiments have been shown that ectopic expression 
of either Sesn1 or Sesn2 downregulates ROS in different cell lines, indicating that Sestrins 
are stress-responsive antioxidant proteins[123]. The important role of the conserved cysteine 
was supported mutation analysis, demonstrating that substitution of the conserved cysteine 
impairs antioxidant activity of Sestrins. Sestrins co-localize and interact with peroxiredoxin1 
(Prx1) and peroxiredoxin2 (Prx2) proteins within the cell and support regeneration of 
overoxidized peroxiredoxins[123]. However, the following studies showed that sulfiredoxin 
protein, unrelated to Sestrin family, plays a major role in regeneration of peroxiredoxins in 
most eukaryotic species and Sestrins do not have intrinsic sulfinil reductase activity[137]. 
Thus, Sestrins play an indirect role in peroxiredoxin signaling working as auxiliary or 
regulatory proteins[1]. According to other observations, the important impact of Sestrins on 
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peroxiredoxin-mediated antioxidant response were demonstrated in macrophages and 
NMDA-stimulated neurons[121, 124].  
Being p53-activated proteins, Sesn1 and Sesn2 mediate antioxidant activities of p53, and 
ectopic expression of Sesn1 and Sesn2 partially restores normal ROS levels, elevated in 
p53-deficient cells[62]. Sesn1 and Sesn2 also suppress DNA-oxidation and mutagenesis 
in p53-silenced lung carcinoma A549 cells [62]. FoxO-inducible gene Sesn3 also inhibits 
ROS accumulation, and AKT stimulates ROS production via FoxO-dependent 
downregulation of Sesn3[117]. As mentioned, FoxOs, similar to p53, regulate ROS in a 
pro-oxidant and an anti-oxidant fashion, dependent upon conditions[15, 138]. In 
response to detrimental genotoxic stress induced by etoposide and doxorubicin, FoxO3A 
stimulates expression of the pro-apoptotic protein Bim and its induction is associated 
with oxidative burst and induction of cell death. Simultaneously, FoxO3A stimulates 
expression of the antioxidant Sesn3 protein, and silencing of Sesn3 accelerates the levels 
of FoxO3A-induced cell death[138]. It is possible that Sestrins set up a protective mode 
against misfired induction of cell death by FoxOs and p53 preventing undesirable cell 
death (Fig.5).  
The antioxidant activities of Sestrins play a potential role in carcinogenesis, and 
inactivation of Sestrins might be desirable for cancer cells, which can exploit the effect of 
Sestrin deficiency on mild ROS production. ROS are involved in mutagenesis and 
genomic instability, associated with selection of more malignant cells, stimulation of cell 
cycle, angiogenesis and epithelial-mesenchymal transition. At the same time, high ROS 
levels can be detrimental for viability of cancer cells, this feature is exploited by some 
anticancer treatments[139]. Mutant Ras proteins induce ROS, which are important for cell 
transformation by the Ras oncogene[140]. Accordingly, expression of Sesn1 and Sesn3 
genes are inhibited by Ras, supporting ROS accumulation in response to Ras 
expression[141]. The expression of both FoxO-dependent genes Sesn1 and Sesn3 were 
decreased in response to Ras, while Sesn2 was not affected [141]. Ras activates AKT 
through stimulation of PI3K and potentially inhibit Sesn1 and Sesn3 via suppression of 
FoxOs[1]. 
7. Regulation of AMPK-TOR signaling by Sestrins  
As antioxidant proteins, Sestrins are potential regulators of many cell signaling pathways 
which are sensitive to redox status in the cell. One of them is the mTORC1-dependent 
pathway, which is regulated by ROS on different levels. ROS directly affect activity of 
mTOR[15] or works upstream via inhibition of different phosphatases, such as PTEN or 
members of the tyrosine phosphatase family, which catalitical cysteine is sensitive to 
inhibitory oxidation [142]. Inactivation of these phosphatases can enhance the signaling 
pathways activated by receptor tyrosine kinases leading to the PI3K-AKT-mTORC1 
activation[15]. Ectopic expression of either member of the Sestrin family suppresses 
mTORC1 activity in different human and mouse cells (Fig.5), as indicated by inhibition of 
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phosphorylation of p70S6K, S6 and 4E-BP proteins[122], similar to effects of rapamycin[122]. 
In complementary experiments knockdown of either Sesn1 or Sesn2 stimulated mTORC1 
activation[122]. Surprisingly, ectopic expression of a redox-deficient mutant of Sesn2 
inhibited mTORC1 with the same efficiency as WT Sesn2 protein, indicating that Sestrins 
regulate mTORC1 in a ROS-independent manner[122].  
To gain insight into the mechanism of mTORC1 regulation, Sesn2 was co-expressed with 
different upstream mTORC1 activators including H-Ras, AKT or Rheb. Sesn2 was able to 
suppress mTORC1 activity in the cells transfected with H-Ras or AKT constructs, but all 
effects of Sesn2 were eliminated by co-expression of Rheb. This data indicates that Sestrins 
regulate mTORC1 downstream of H-Ras and AKT but upstream of Rheb[122]. Rheb-GTP 
analysis in breast carcinoma MCF7 cells demonstrated that induction of Sesn2 strongly 
inhibited Rheb-GTP loading, indicating an inhibitory effect of Sestrins on Rheb[122].  
Rheb activity is regulated by the TSC1:TSC2 protein complex and Sestrins inhibit Rheb in a 
TSC2-dependent manner. The following experiments showed that Sestrins regulated 
TSC1:TSC2 activity not trough regulation of upstream TSC2 kinases AKT and ERK [122]. 
AMPK is the kinase which directly phosphorylates and activates TSC2 in response to stress 
and we have shown that either Sesn1 or Sesn2 stimulate AMPK phosphorylation on Thr172 
followed TSC2 phosphorylation and activation by AMPK [122] (Fig.5). Moreover, it has been 
demonstrated that Sesn2 stimulates expression of AMPK subunits in response to DNA-
damage[143]. An inhibition of mTORC1 in an AMPK- and TSC2-dependent manner was 
demonstrated later for Sesn3[118]. 
To examine whether Sesn2 can be directly involved in TSC2 and AMPK activation, 
purification and analysis of Sesn2-containing protein complexes were performed in gel-
filtration experiments. As shown, Sesn1 and Sesn2 were co-eluted in a high molecular 
weight fractions (411-1175 kDa), together with the TSC1, TSC2 and AMPK proteins[122]. 
Immunoprecipitation of protein complexes with anti-Sesn2 antibodies allowed us to co-
purify AMPK1 and AMPK2 subunits and the TSC1:TSC2 complex with Sesn2, 
indicating an interaction of Sestrins with the AMPK, TSC1 and TSC2 proteins [122]. 
Moreover, we observed binding of GST-Sesn2 with AMPK proteins, supporting the idea 
that Sestrins activate AMPK via direct protein-protein interactions (AVB, 
unpublished)[122].  
The inhibition of mTORC1 by Sestrins has an impact on many mTORC1-dependent 
processes including translation, cell growth and proliferation. Accordingly, significant 
downregulation of CyclinD1 and c-Myc expression was observed in breast carcinoma MCF7 
cells in response to Sesn2 induction[122]. The mechanism of inhibition of protein synthesis 
by Sestrins involves formation of the 4EBP1- eIF-4E complex, which suppresses initiation of 
translation of the Cap-dependent mRNAs[122]. Being stress-inducible proteins, Sestrins are 
potential regulators of protein synthesis in response to stress. Accordingly, it has been 
shown that Sesn1 and Sesn2 play a critical role in inhibition of protein synthesis in response 
to -irradiation in breast epithelial MCF10A cells [144]. 
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Regulation of translation and metabolism via mTORC1 inhibition strongly affects cell 
growth, proliferation and cell viability. Accordingly, ectopic expression of Sestrins in 
different cell lines causes a decrease in cell size as compared to GFP control, supporting 
the inhibitory role of Sestrins on cell growth[122]. Cell growth is linked with cell 
proliferation, and we showed that Sestrins inhibited cell proliferation in many cell types 
such as human lung carcinoma H1299, human fibrosarcoma HT1080, human breast 
carcinoma MCF7 and human immortalized fibroblasts from Li-Fraumeni patient 
MDA041[119]. Using matched HCT116 cells with normal p53 and p21 status, p53-deficient 
or p21-deficient cells, we also showed that the inhibition of cell proliferation by Sestrins 
was p53- and p21- independent (AVB and Chumakov PM, unpublished). Sestrins 
inhibited cell proliferation as evident by accumulation of cells in the G1 phase of the cell 
cycle after Sesn2 overexpression[122]. To confirm the importance of mTORC1 in the 
regulation of cell growth and proliferation Sesn2 was ectopically expressed in TSC2-
deficient cells, and no effects on cell growth and proliferation were observed in the 
absence of TSC2 protein[122]. 
AMPK activation and mTORC1 inhibition also regulates autophagy through 
phosphorylation of ULK1 kinase and we showed that Sestrins stimulated autophagy in 
H1299 cells (AVB and Karin M, unpublished). It has been demonstrated that Sesn2 regulates 
autophagy in response to rapamycin, nutrient-free medium, thapsigargin (an activator of 
endoplasmic stress), and lithium in human colon carcinoma HCT116 cells [145]. The 
activation of autophagy in response to these stimuli requires p53, and autophagy was 
significantly inhibited in HCT116 p53-null cells. The potential explanation for this effect is 
that expression of Sesn2 and other p53-dependent proteins involved in autophagy such as 
Sesn1, DRAM, LC3 and ULK1 is supported by p53[15, 20, 74, 146]. Accordingly, silencing of 
DRAM, another important regulator of autophagy, had similar inhibitory effects on 
autophagy as Sesn2 knockdown [145] (Fig.5). 
The effects of Sestrins on cell physiology is not only limited to regulation of cell proliferation 
but also involves regulation of cell viability. Sesn2 overexpression in 293 cells stimulates cell 
death[119]. Sestrins also modulate cell viability under stress condition, protecting from 
oxidative stress, but supporting cell death in response to genotoxic stress[119, 123, 143, 147]. 
Cell death in response to -irradiation is regulated in an AMPK-dependent manner and 
Sesn2 plays a major role in regulation of AMPK phosphorylation in response to genotoxic 
stress[40, 41, 143].  
The prominent role of p53 in the regulation of Sesn1 and Sesn2, and FoxOs in the regulation 
of Sesn3, make Sestrins potential mediators of p53 and FoxO-dependent processes. We 
showed that silencing of either Sesn1 or Sesn2 released the inhibitory effects of p53 on 
mTORC1 in different experimental contexts including overexpression of p53 in p53-deficient 
H1299 cells, stimulation p53 by Nutlin-3 in U2OS cells and activation by the genotoxic drug 
camptothecin in mouse embryonic fibroblasts[122]. Moreover, Sesn2 regulates mTORC1 
activity in vivo in mouse liver in response to treatment with the alkylating liver-specific 
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poison diethylnitrosamine[122]. Another group also demonstrated that fangchinoline, bis-
benzylisoquinoline alkaloid, which is considered as new antitumor agents, activated Sesn2 
expression through p53 and regulates autophagy via activation of AMPK kinase[148]. 
Interestingly, fangchinoline is able to stimulate cell death through induction of autophagy, 
explaining the potential role of Sestrins in support of cell death in response to some 
stimuli[119]. p53 can be inactivated in many cancer cells through interaction with inhibitory 
proteins, which might be potential targets for anticancer treatment. In lung cancer cell lines 
p53 is bound to and inactivated by orphan nuclear receptor Nur77/TR3. Nur77 suppression 
by siRNA released p53, which in turn stimulated Sesn2. It led to AMPK activation and 
mTORC1 suppression, resulting in inhibition of growth and inducing apoptosis in lung 
carcinoma cells[149]. 
The regulation of the AMPK-TORC1 axis by Sestrins is highly conserved in evolution. We 
showed that similar to mammalian Sestrins, dSesn inhibited TORC1, as indicated by 
diminished levels of p70S6K phosphorylation, in an AMPK- and TSC2-dependent manner. 
Inactivation of dSesn led to many abnormalities associated with AMPK-TORC1 
dysregulation, such as metabolic derangements and oxidative stress. Interestingly, the 
effects of dSesn inactivation can be normalized by reconstitution with mammalian Sestrins, 
while dSesn activates mammalian AMPK and inhibits mTORC1, indicating the highly 
conservative functions of Sestrins[135]. 
8. Regulation of TGF signaling by Sesn2 
The AMPK-TOR axis is not the only signaling pathway modulated by Sestrins. A new role 
of Sestrins was described in the control of transforming growth factor- (TGF) signaling. 
TGF signaling is regulated by binding of a dimer of TGF ligands (composed of TGF1,2 3) 
with TGF receptor (TGFR 1 and 2), stimulating its heterodimerisation and activation of its 
intrinsic Ser/Thr kinase activity[150, 151]. Cells secrete TGF as large latent complex 
containing one of three latent TGF binding proteins LTBP1, LTBP2 and LTBP4 belonging to 
the fibrillin family of extracellular matrix (ECM) proteins[150]. LTBPs target TGF to ECM 
depositing them for mobilization when activation of TGF- signaling is required. Activated 
TGF-R transduces a signal to proteins of the Smad family, classified as receptor-associated 
Smads (R-Smads: Smad 1,2,3,5&8), cooperating Smads (Co-Smads: Smad4) and inhibitory 
Smads (i-Smads: Smad6&7). It was shown that R-Smads, Smad1-5, are substrates of TGF 
receptors, activated by TGF, while others are activated by other members of the TGF 
family via interaction with relevant receptors. Phosphorylated Smad2 and Smad3 form 
heteromeric complexes with Smad4, which translocate to the nucleus where they bind 
Smad-dependent promoters and activate expression of a number of genes such as -smooth 
muscle actin (SMA), connective tissue growth factor (CTGF) and matrix metalloproteinase 2 
(MMP2) involved in regulation of cell growth, differentiation and migration[147, 152]. TGF 
also controls other signaling pathways through RhoA, Cdc42, Rac1, Ras, PI3K, PP2A, 
MEKK1, TAK1 and DAXX proteins. Dysregulation in TGFb-dependent signaling contributes 
to fibrosis, cancer, cardiovascular and congenital diseases[150]. Sesn2-deficiency leads to 
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activation of TGF signaling pathways in lung as well as in mouse lung fibroblasts (MLF) as 
indicated by increased phosphorylation of Smad2 and Smad3, and elevated expression of 
TGFb targets such as -SMA, connective tissue growth factor (CTGF) and MMP2[147]. It has 
been also shown that inactivation of Sesn2 in MLF activates mTORC1, and TGF played a 
role in this process potentially stimulating the PI3K-AKT pathway[147] (Fig.5). TGF 
pathway is not the only receptor-activated cascade is regulated by Sestins. As reported 
recently, inactivation of Sesn2 also caused accumulation of platelet-derived growth factor 
receptor- (PDGFR) in glioblastoma U87 cells. PDGFR was accumulated in Sesn2-silenced 
cell due to impaired ubiquitination and degradation. These cells had increased ROS 
production and higher rate of autophagy, which can indicate a compromised 
metabolism[153]. 
 
Figure 5. Functions of Sestrins. Sestrins suppress ROS accumulation, inhibit the TGF pathway and 
activate AMPK causing suppression of mTORC1. As a result, Sestrins control many mTORC1-
dependent processes such as translation, metabolism, cell growth and autophagy. Inhibition of ROS by 
Sestrins prevents mutagenesis and genetic instability, the hallmarks of carcinogenesis. Being targets of 
p53 and FoxOs, Sestrins mediate many p53- and FoxO-regulated processes including regulation of ROS 
and metabolism potentially contributing to regulation of longevity by these transcriptional factors. 
9. Role of Sestrins in aging and diseases 
Aging and age-related diseases can be caused by deterioration of the mechanisms 
controlling stress responses which prevent accumulation of damaged organelles, 
macromolecular aggregates and ROS in cells through control of anabolic and catabolic 
processes. Two important functions of mTORC1, such as control of protein synthesis and 
autophagy are critical for lifespan regulation and fitness, and the pathways, which enhance 
or suppress mTORC1 activity, may contribute to longevity and health[6]. The members of 
the Sestrin family are antioxidant proteins involved in suppression of TORC1, so they are 
potential regulators of aging and longevity. 
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9.1. Role of Sestrins in aging 
The redundancy of the Sestrin family members in mammals complicates the analysis of 
function of Sestrins in aging and diseases. To gain insight into the role of Sestrins in the 
regulation of aging, Drosophila Melanogaster containing only one Sesn gene (dSesn), was 
chosen as a convenient model. TORC1 is a critical regulator of aging and lifespan in 
Drosophila, and activity of TORC1 is elevated in dSesn-null flies[135]. Also, we have shown 
dSesn is induced in response to activation of InR, which stimulate activity of dTOR. dTOR is 
involved in activation of dSesn through ROS production, which induces JNK followed by 
activation of dFoxO. AKT, stimulated in response to InR in the same system, is a negative 
regulator of dFoxO. Thus the signals from AKT and JNK compete for regulation of this 
transcription factor, with JNK providing the dominant signal. dSesn is induced in response 
to InR-JNK-dFoxO activation and inhibits TORC1, providing a negative feedback loop 
toward regulation of InR-AKT-dTOR signaling[135]. Overactivated InR signaling 
contributes to many age-related pathologies in flies including metabolic derangement and 
heart and muscle deterioration, so dSesn might have a protective role against these 
diseases[1, 135]. 
Accordingly, the dSesn-deficient flies have many health-related problems. First, the flies 
have impaired lipid metabolism and accumulate lipids (Fig.6). The mechanisms of lipid 
regulation involve two processes: lipogenesis and lipolysis. TOR controls lipolysis through 
activation of transcriptional factor SREBP. We observed that expression of dSREBP and its 
targets dFAC, dFAS, dACC and dACS were up-regulated in dSesn-deficient animals, while 
the expression of the genes involved in lypolisis such as dPGC1, lip3, CG5966, CG11055 
were downregulated. Interestingly, the accumulation of lipids in dSesn-deficient flies was 
prevented by treatment of flies with either AMPK activators AICAR or metformin, or TOR 
inhibitor - rapamycin[135].  
Second, dSesn-null flies demonstrated heart dysfunction manifested in arrhythmia and 
decreased heart rate due to expansion of diastolic period. This phenotype was largely 
prevented when flies were treated with AICAR and rapamycin, indicating the role of 
AMPK-TOR signaling in this process. The activated TOR signaling is associated with ROS 
accumulation. To examine whether ROS contribute to the phenotype, ROS were suppressed 
by antioxidant vitamin E or via expression of catalase in heart muscle. Strikingly, both 
conditions suppressed arrhythmia in dSesn-deficient flies but did not prevent the decrease in 
heart rate, indicating some ROS-independent effects of dSesn on heart protection. We also 
observed massive disorganization of myofibrils indicated by F-actin staining in dSesn-null 
flies. Thus, dSesn might be important for prevention of heart degeneration associated with 
activated TOR signaling[135] (Fig.6). 
Third, inactivation of dSesn had a detrimental effect on thoracic (skeletal) muscle. The flies 
were characterized by muscle degeneration as evidenced by loss of sarcomeric structure and 
diffused sarcomeric boundaries. The muscles exhibited mitochondrial abnormalities such as 
rounded shape, enlargement and cristae disorganization. Oxidative stress is the typical 
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feature of mitochondrial malfunction and muscle from dSesn-null flies showed an increased 
accumulation of ROS. The detrimental muscle phenotype evoked by dSesn inactivation was 
prevented by treatment with antioxidant vitamin E, supporting the idea that ROS contribute 
to muscle degeneration. Deterioration of muscle structure, associated with mitochondrial 
abnormalities and oxidative stress might be linked to impaired autophagy, the important 
mechanism for control of muscle cell integrity and function. The defects in autophagy, the 
controller of muscle integrity, in dSesn-deficient flies was evident from accumulation of 
ubiquitinated protein aggregates, which are cleared via autophagic proteolysis. To examine 
the potential impact of autophagy on regulation of cardiac and muscle homeostasis we 
knocked down the ULK1(ATG1) gene, the critical component of the autophagic machinery, 
which is inhibited by TOR and activated by AMPK. Silencing of ULK1 had effects similar to 
dSesn inactivation such as cardiac deficiency, muscle degeneration, mitochondrial 
abnormalities and oxidative stress[135]. 
The phenotypes observed in young (2-3 weeks old) dSesn-deficient flies resembled those 
in old WT flies, indicating that dSesn-null flies in early age have many features of aging 
animals[135]. Thus dSesn controls processes important for homeostasis, which being 
improperly regulated can accelerate aging. These processes potentially involve the 
mechanisms of stress response, which act to repair or remove damaging consequences of 
stress. Aging and age-related diseases might be a result of unresolved stress which lead 
to accumulation of damage causing more intense stress, supporting a vicious cycle 
(Fig.6).  
Although the data on the role of Sestrin in aging in vertebrates are scant, there is some 
evidence that Sestrins might play an important role in protection against aging and age-
related diseases in mammals. Strong activation of Sesn1 and Sesn2 was found in s-Arf/p53 
mice[90], which demonstrated delayed aging and were protected from carcinogenesis. The 
activities of AMPK and p53 decline with age as well as the levels of autophagic 
proteolysis[51, 93, 154]. Sestrins being a link between p53 and AMPK might be suppressed 
in aging animals, and as a result this dysregulation can weaken the mechanisms protecting 
their health. 
9.2. Sestrins and neurodegenerative diseases 
The pathogenesis of many neurodegenerative diseases, such as Alzheimer’s, Parkinson’s 
and Huntington’s disease are associated with accumulation of protein deposits, which can 
affect cell physiology and induce oxidative stress and cell death[1]. Inhibition of mTORC1 
has a protecting effect by suppressing accumulation of protein deposits, potentially via 
inhibition of protein translation and activation of autophagy[1, 3]. Sesn2 was activated in 
human neuroblastoma CHP134 cells in response to amyloid -peptides, the toxic deposits 
found in the brain of Alzheimer patients[127]. In another study Sesn2 was found to co-
localize with Tau, another protein forming deposits or tangles in neurons, in a subset of 
neurofibrillary lesions[155]. Pathogenesis of neurodegenerative diseases is associated with 
oxidative stress and accordingly Sesn2 was activated by ROS in neurons, where Sesn2 plays 
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an antioxidant role[124]. Thus, Sestrins can protect neuronal cells from the toxic effects of 
neuronal deposits and oxidative stress. The other member of the Sestrin family, Sesn1 was 
activated in response to the neuroprotective drug rosiglitazone, a member of the 
thiazolidinedione family of synthetic peroxisome proliferator-activated receptor (PPAR) 
agonists. Rosiglitazone protects retinal cells from cell death mitigating the effects of ROS 
and Ca2+, so Sesn1 might be a critical target of this drug involved in regulation of cell 
viability[156] (Fig.6).  
9.3. Sestrins and diabetes 
Dysregulation of the AMPK-mTORC1 pathway and ROS metabolism contributes to type II 
diabetes and Sestrins and their regulator p53 might play a protective role against this 
disease. According to resent observations, knockin mice where p53 Ser18 (analog of Ser15 in 
human) was replaced by alanine, showed increased metabolic stress and develop insulin 
resistance and glucose intolerance, the hallmarks of type II diabetes[157]. Ser18 is the site of 
phosphorylation of ATM kinase. Inactivation of ATM induces metabolic derangements and 
development of diabetic phenotype in mice. According to a hyperinsulinemic-euglycemic 
clamp study, diabetic phenotype of p53S18A mice was evoked by reduction of insulin-
stimulated whole-body glycogen synthesis and inefficient suppression of hepatic glucose 
production by insulin. These mice had decreased levels of expression of Sestrin family 
members in liver, muscle and white adipose tissue, suggesting that downregulation of 
Sestrins in the p53S18A mice contributed to the diabetic phenotype. Impressively, 
downregulation of Sesn2 and Sesn3 genes was also observed in ATM+/- mice where ATM 
activity was reduced[157]. The fibroblasts from p53S18A mice were characterized by increased 
ROS levels associated with reduced expression of all members of Sestrin family. Ectopic 
expression of Sesn2 in the p53S18A fibroblasts restored normal ROS levels, supporting the 
critical role of Sestrins in ROS regulation in p53S18A mice. To study whether the diabetic 
phenotype of the p53S18A mice was linked with oxidative stress, associated with a 
compromised p53 function, the mice were treated with butylated hydroxyanisole (BHA). 
BHA treatment suppressed diabetic phenotype in the p53S18A mice supporting the role of 
oxidative stress associated with p53 dysfunction in diabetes[157] (Fig.6). 
9.4. Sestrins and respiratory diseases 
Antioxidant effects of Sestrins might also be important in protection of respiratory 
epithelium via control of barrier function. Pollutant-induced inflammation compromises the 
barrier function, which leads to different respiratory diseases such as asthma, cystic fibrosis, 
and chronic obstructive pulmonary disease (COPD). The barrier function of the respiratory 
epithelium is protected by trasncriptional factor HIF1 fortifying an antioxidant defense, and 
this function is associated with activation of Sesn2, which seems to be a critical HIF1 target 
involved in this process[120]. Interestingly, according to another work, Sesn2 activity can 
complicate some aspects of COPD via negative regulation of TGFβ signaling which 
mitigates emphysema phenotype in mice. Thus, inactivation of Sestrins has some 
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therapeutic potential under some COPD conditions, although more work has to be done to 
elucidate the exact role of Sestrins in COPD and other respiratory diseases[147].  
9.5. Sestrins and cancer 
Tumor suppressor p53, the master regulator of Sesn1 and Sesn2, is inactivated in most of 
human cancers, and p53 inactivation causes downregulation of Sesn1 and Sesn2, which 
can be responsible for tumor suppressive activities of p53 [62, 114, 119, 123]. Tumor 
suppressor activity was also recently assigned for the members of the FoxO family. 
Somatic inactivation of three members of the FoxO family: FoxO1, FoxO3A and FoxO4 in 
mice stimulated development of lymphomas and hemangiomas[158, 159]. Sesn1 and 
Sesn3 are FoxO targets, which can potentiate the tumor suppressive effects of FoxOs via 
regulation of ROS. The potential tumor suppressive activity of Sestrins and their impact 
on p53 and FoxO-mediated tumor suppression might involve antioxidant defense 
imposed by Sestrins, which can protect from mutagenesis, genomic instability and 
angiogenesis, as well as can regulate some other cancer-relevant processes associated 
with dysregulation of ROS metabolism[62, 141]. The role of Sestrins in many types of 
cancer is strengthened by the importance of Sestrins in regulation of the LKB1-AMPK-
mTORC1 pathway[52, 122]. In agreement with this, it was observed that Sesn2-deficient 
cells are more susceptible to transformation than WT counterparts and Sesn2-silenced 
A549 tumor xenografts grow faster in nude mice, similar to p53-deficeint cells[62, 122] 
(Fig.6).  
Analysis of human tumors demonstrates that loss of heterozygosity (LOH) in Sesn1 
(6q21) found in non-Hodgkin lymphoma, acute lymphoblastic leukemia, bladder 
carcinoma, ovarian, mammary carcinomas, squamous cell carcinomas of the head and 
neck, T cell lymphomas[160] and Sesn2 (1p34) loci found in pancreatic 
adenocarcinoma[161], glioblastoma[162], T-cell lymphomas[160], ovarian cancers [163], 
thyroid cancers [164], and neuroblastomas[165]. LOH in the Sesn3 locus (11q21) is found 
in non-Hodgkin lymphoma[166], nasopharyngeal carcinoma[167, 168], pancreatic 
endocrin tumors[169], and melanomas[170]. Analysis of gene expression have shown 
that Sesn1 and Sesn2 are downregulated in lung cancers of different origin such as large 
cell carcinoma, adenocarcinoma, squamos cell carcinoma and small cell lung 
carcinoma[171-173]. Sesn1 is also found downregulated in breast cancers[174, 175], head 
and neck cancers[176], brain tumors[177] and T-cell leukemia/lymphoma[177]. Moreover, 
missense mutation of Sesn2 P87S was recently found in myeloproliferative neoplasm 
essential thrombocythemia (ET), characterized by increased proliferation of 
megakariocytes and accumulation of circulated platelets[178]. Another mechanism of 
inactivation of the members of the Sestrin family was described for endometrial cancers, 
where Sesn3 is methylated in 20% of cases, supporting the potential role of this gene in 
tumor suppression [179]. Although more extensive analysis is required to label Sestrins 
as tumor suppressors, these data clearly indicate the indispensable impact of Sestrins in 
control of carcinogenesis. 
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The regulation of the TGF pathway by Sestrins can also contribute to carcinogenesis. 
Although TGF can inhibit cell growth and suppress carcinogenesis at early stages, during 
the late stages of carcinogenesis cells often lose their growth-inhibitory response to TGF. 
Moreover, TGFstimulates invasion and metastasis of cancer cells supporting tumor 
progression. Accordingly, overexpression of TGF1 was found in breast, colon, esophageal, 
gastric, hepatocellular lung and pancreatic cancers. Moreover, high levels of TGF correlate 
with cancer progression, metastasis, angiogenesis and bad prognosis[152]. Inactivation of 
Sestrins can stimulate TGF signaling and potentiate TGF-dependent processes 
contributing to carcinogenesis. The link between Sestrins and TGF in human cancers and 
the impact of TGF-dependent pathway in regulation of carcinogenesis by Sestrins has to be 
addressed in the future studies. 
 
Figure 6. Sestrins protect from aging and age-related diseases. Drosophila Sestrin protect flies from 
aging, suppressing metabolic derangements, cardiac malfunction and muscle degeneration. In 
mammals, Sestrins are activated in the mice with delayed aging phenotype, while decreased expression 
of Sestrins is observed in diabetic mice. Moreover, Sestrins are found downregulated in many cancers. 
The conservatism of the mechanisms of regulation of longevity and aging between vertebrates and 
invertebrates via the AMPK-TORC1 pathway support the critical role of Sestrins in regulation of aging 
at mammals and their protecting activities against age-associated diseases. 
Being stress-inducible genes, Sestrins are activated by many anticancer treatments, which 
involve stress response. Although the stress might be detrimental for cancer cells inducing 
cell death and senescence, which suppress tumor growth, cancer cells can eventually 
accumulate mutation in genes critical for the beneficial effects of anti-cancer therapy. 
Sestrins are important for cell death in response to genotoxic stress[119, 143], so they might 
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be targets for inactivation in response to therapy. Presumably reactivation of Sestrins might 
be beneficial for treatments involving genotoxic stress. On the contrary, Sestrins might 
protect against oxidative stress, which also contributes to death of cancer cells, so under 
some circumstances inactivation of Sestrins might be beneficial for the treatment efficiency. 
Thus, the detailed characterization of the role of Sestrins in the efficiency of anticancer 
treatment is very important to set up the best treatment strategy for different forms of 
cancer. 
10. Conclusion 
A decade ago we identified a novel Sestrin gene family which happens to be in the 
intersection of two vital roads controlled by two important guards, p53 and FoxOs, the 
grants of our well-being and longevity. Sestrins convey the message from them to the 
AMPK-TORC1 executive branch, responsible for integration of numerous signals from 
nutrient and energy sources, growth factors, hormones and stress insults to tune up many 
metabolic, biosynthetic and disposing facilities providing good conditions for the organism 
well-being. Unfortunately, some hereditary or environmental factors, including an 
unhealthy life style, can impair the guards and release the malfunctioning machine of TOR 
signaling leading to non-synchronized anabolic and catabolic process resulting in the 
accumulation of damage, the major source of our demise. The absence of careful control of 
these processes also lead to disturbances in different tissues laying the ground for many 
detrimental age-related diseases, the major threat of developed societies in the 21st century. 
The restoration of the guards’ functions, in part, via enabling Sestrins that are important 
messengers of their orders, might prove to be a valuable approach to delay or prevent many 
undesirable manifestations of aging and unhealthy life style. Future experiments on mouse 
genetic models and detailed analysis of the role of Sestrins in human diseases let us establish 
the impact of Sestrins in the control of human health and longevity, understand the 
mechanisms of their action and exploit this knowledge for the development of efficient anti-
aging therapies. 
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